READDI | Advancing Antiviral Drug Discovery with AI | SAS Customers

The Rapidly Emerging Antiviral Drug Development Initiative (READDI) is a public-private biotechnology company dedicated to discovering antiviral drugs ahead of the next pandemic. The organization’s work focuses on single drugs that work against multiple related viruses.
Dr. Nat Moorman is READDI’s Co-founder and Associate Professor in the UNC School of Medicine’s Department of Microbiology and Immunology. Moorman and SAS’ Rachel Hardin discuss their organizations’ partnership. READDI is working with SAS to bring together lab and electronic health record data and apply AI and machine learning models to better understand viral disease and find new targets for antiviral drugs.
Learn More about SAS Software
◉ Life Sciences Analytics - www.sas.com/lifesciences
◉ SAS Viya - AI and Analytics Platform - www.sas.com/viya
◉ The Health Pulse Podcast - www.sas.com/thehealthpulse
◉ Contact Us - www.sas.com/contact
SUBSCRIBE TO THE SAS SOFTWARE UA-cam CHANNEL
ua-cam.com/users/SASSoftware?s...
ABOUT SAS
SAS is a trusted analytics powerhouse for organizations seeking immediate value from their data. A deep bench of analytics solutions and broad industry knowledge keep our customers coming back and feeling confident. With SAS®, you can discover insights from your data and make sense of it all. Identify what’s working and fix what isn’t. Make more intelligent decisions. And drive relevant change. #SASSoftware #SASSoftware
CONNECT WITH SAS
SAS ► www.sas.com
SAS Customer Support ► support.sas.com
SAS Communities ► communities.sas.com
SAS Analytics Explorers ► explorers.sas.com
Facebook ► / sassoftware
Twitter ► / sassoftware
LinkedIn ► / sas
Blogs ► blogs.sas.com
RSS ► www.sas.com/rss